RENVELA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $25,664 | 8 | 1 |
| 2018 | $266.62 | 14 | 14 |
| 2017 | $132,149 | 2,266 | 1,246 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $79,829 | 10 | 50.5% |
| Food and Beverage | $40,183 | 2,244 | 25.4% |
| Travel and Lodging | $27,238 | 24 | 17.2% |
| Unspecified | $5,498 | 7 | 3.5% |
| Consulting Fee | $5,332 | 3 | 3.4% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease | GENZYME CORPORATION | $5,498 | 7 |
Top Doctors Receiving Payments for RENVELA — Page 10
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Nephrology | Broussard, LA | $48.13 | 3 |
| , MD | Internal Medicine | Englewood, NJ | $48.07 | 3 |
| , MD | Nephrology | Englewood, NJ | $48.07 | 3 |
| , MD | Nephrology | Englewood, NJ | $48.07 | 3 |
| , MD | Nephrology | Englewood, NJ | $48.07 | 3 |
| , M.D | Specialist | Brooklyn, NY | $47.97 | 2 |
| , MD | Nephrology | New York, NY | $47.81 | 2 |
| , D.O | Nephrology | Monroe, NJ | $47.70 | 2 |
| , M.D | Nephrology | Des Moines, IA | $47.66 | 3 |
| , M.D | Nephrology | Fairfax, VA | $47.63 | 3 |
| , MD | Nephrology | Detroit, MI | $47.60 | 2 |
| , MD | Nephrology | Scottsdale, AZ | $47.53 | 3 |
| , M.D | Internal Medicine | Houston, TX | $47.52 | 2 |
| Patrick Fluck | Nephrology | Hutchinson, KS | $47.51 | 2 |
| , M.D | Nephrology | Jacksonville, NC | $47.00 | 3 |
| , MD | Nephrology | El Paso, TX | $47.00 | 4 |
| , M.D | Nephrology | Wauwatosa, WI | $46.97 | 3 |
| Barry Chantrelle | — | Oakland, CA | $46.84 | 2 |
| , M.D | Nephrology | Orange, CT | $46.84 | 2 |
| , M.D | Internal Medicine | Bridgeport, CT | $46.83 | 2 |
| , MD | Nephrology | Lafayette, IN | $46.83 | 2 |
| , MD | Internal Medicine | New York, NY | $46.83 | 2 |
| , D.O | Nephrology | Whitehall, PA | $46.72 | 2 |
| , M.D | Nephrology | Waipahu, HI | $46.66 | 2 |
| , M.D | Nephrology | Mc Lean, VA | $46.39 | 2 |
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $131,370
- GENZYME CORPORATION $26,710
Product Information
- Type Drug
- Total Payments $158,080
- Total Doctors 1,251
- Transactions 2,288
About RENVELA
RENVELA is a drug associated with $158,080 in payments to 1,251 healthcare providers, recorded across 2,288 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2017 to 2019. In 2019, $25,664 was paid across 8 transactions to 1 doctors.
The most common payment nature for RENVELA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($79,829, 50.5% of total).
RENVELA is associated with 1 research study, including "Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease" ($5,498).